Abstract
Within 12 years of the discovery of Helicobacter pylori and recognition of its importance in ulcer disease, highly effective 1-week regimes for its eradication had become widely used1–3. This rapid progress was achieved with results from a relatively small number of trials that were very pragmatic and often under-powered4, an interesting illustration of the fact that progress can, and usually does, occur in the absence of orthodox research design. As a result, management of H. pylori-associated peptic ulcer has been revolutionized by becoming substantially better and substantially cheaper.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bazzoli F, Gullini S, Zagari RM et al. Effect of omeprazole and clarithromycin plus tinidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. Gut. 1995;37(Suppl. 1):5.
Bazzoli F. Italian omeprazole triple therapy — a 1-week regimen. Scand J Gastroenterol. — Suppl. 1996;215:118.
Labenz J., Stolte M, Ruhl GH et al. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995;7:9–11.
Sherwood 2000 in preparation
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD and the RBC H. pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10:251–261.
Goddard AF, Jessa MJ, Barrett DA et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology. 1996;111:358–367.
Sherwood PV, Wibaud JI, Goddard AF, Barrett DA, Shaw PN, Spiller RC. Acid secretion determines gastric metronidazole transfer. Gastroenterology. 1999;116:A309.
Houben MHMG, van de Beek D, Hensen EF, De Craen AJM, Rauws EAJ, Tytgat GNJ. A systematic review of Helicobacter pylori eradication therapy — the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047–1055.
Borody TJ, Brandi S, Andews P, Ferch N, Jankiewicz E, Hyland L. Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. Am J Gastroenterol. 1994;89:33–38.
Duggan AE, Tolley K, Hawkey CJ, Logan RFA. H. pylori eradication in duodenal ulcer disease: what determines cost effectiveness? Br Med J. 1998;316:1648–1654.
Huwez FU, Thurlwell D, Cockayne A, Ala-Aldeen DA. Mastic gum kills Helicobacter pylori. N Engl J Med. 1998;339:1946.
Lee M, Kern JA, Canning A, Egan C, Tataronis G, Francis F. A randomized controlled trial of an enhanced patient compliance programme for Helicobacter pylori therapy. Arch Intern Med. 1999;159:2312–2316.
Henry A, Batey RG. Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study. Am J Gastroenterol. 1999;94:811–815.
Megraud F. Risk factors for failures. In: Hunt RH, Tytgat GJ, editors. Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000; this volume.
Hazell S. What are the biochemical and physiological implications of the new genetic information? In: Hunt RH, Tytgat GJ, editors. Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000; this volume.
Marais A, Mendz GL, Hazell SL, Megraud F. Metabolism and genetics of Helicobacter pylori: the genome era. Microbiol Mol Biol Rev. 1999;63:642–674.
Tomb J-F, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997;388:539–547.
Alm RA, Ling L-SL, Moir DT et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999;397:176–180.
O’Toole PW, Janzon L, Doig P, Huang J, Kostrzynska M, Trust TJ. The putative neura-minyllactose-binding hemagglutinin HpaA of Helicobacter pylori CCUG 17874 is a lipoprotein. J Bacteriol. 1995;177:6049–6057.
Boren T, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science. 1993;262:1892–1895.
Zopf D, Roth S. Oligosaccharide anti-infective agents. Lancet. 1996;347:1017–1021.
Sachs G. Urease regulations. In: Hunt RH, Tytgat GJ editors. Helicobacter pylori: Basic Mechanisms to Clinical Cure 2000; this volume.
Jackson CJ, Kelly DJ, Clayton CL. The cloning and characterization of chemotaxis genes in Helicobacter pylori. Gut. 1995;37:A71.
O’Toole PW, Kostrazynska M, Trust TJ. Non-mobile mutants of Helicobacter pylori and Helicobacter mustelae defective in flagellar hood production. Mol Microbiol. 1994,14:691–703.
Sega ED, Cha J, Falkow S, Tompkins LS. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori Proc Natl Acad Sci USA. 1999;96:14559–14564.
Mysore JC, Wiggington T, Simon PM, Zopf D, Heman-Ackah LM, Dubois A. Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound. Gastroenterology. 1999;117:1316–1325.
Graham DY., vacA, cagA, iceA and babA are not useful for assessing H. pylori virulence. In: Hunt RH, Tytgat GJ, editors. Helicobacter pylori: Basic Mechanisms to Clinical Cure. 2000; this volume.
Duggan AE, Elliott C, Hawkey CJ, Logan RFA. Randomised controlled trial of four dyspepsia management strategies in primary care with 12 months follow-up. Gastroenterology. 2000 (In press).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Hawkey, C.J. (2000). Helicobacter pylori infection: expectations for future therapy. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobacter pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-3927-4_69
Download citation
DOI: https://doi.org/10.1007/978-94-011-3927-4_69
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5753-0
Online ISBN: 978-94-011-3927-4
eBook Packages: Springer Book Archive